Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neurobioma is a topical active cosmetic and emollient complex developed by La Roche-Posay (a brand of L'Oréal) specifically designed to break the vicious itch-scratch cycle in atopic dermatitis. The complex is a synergistic combination of three active ingredients: Aqua Posae Filiformis (APF), a patented postbiotic biomass of Vitreoscilla filiformis; Microresyl, a patented extract from Ophiopogon japonicus root; and an antiprotease peptide (commercially known as Proteasyl, derived from Pisum sativum/pea extract). Together, these components work to rebalance the skin microbiome, inhibit Staphylococcus aureus biofilm formation, and prevent the activation of Protease-Activated Receptor-2 (PAR2) on sensory neurons and keratinocytes by inhibiting epidermal serine proteases (such as KLK5, KLK7, KLK14, and mast cell tryptase). This multi-target approach effectively reduces pruritus and restores skin barrier integrity. It is formulated in the commercial emollient Lipikar Baume AP+Max (also known as Lipikar AP+Max Triple Repair Moisturizing Cream).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neurobioma.